Analysis Group Study Highlights Treatment Patterns and Resource Use Among Patients with Advanced Bladder Cancer Pre-Enfortumab Vedotin
July 16, 2025
Urothelial carcinoma (UC) is the predominant type of bladder cancer, as more than 90% of urothelial tract tumors originate in the bladder. Among patients with UC, approximately one quarter are diagnosed with a more advanced disease, such as locally advanced/metastatic urothelial carcinoma (la/mUC). Enfortumab vedotin (EV) monotherapy has emerged as an effective treatment option for patients with la/mUC who have received one prior line of therapy and are ineligible for platinum-based chemotherapy. EV received accelerated approval from the US Food and Drug Administration (FDA) in December 2019 and full approval in July 2021.
To better understand the real-world use of EV, an Analysis Group team led by Managing Principal Hongbo Yang, Managers Angela Lax and Qing Liu, and Associate Alexandra Greatsinger collaborated with researchers from Pfizer, Astellas Pharma, and the Dana-Farber Cancer Institute. Together, they conducted a first-of-its-kind study examining real-world patient characteristics, treatment patterns, and health care resource use (HRU) and costs among US patients with la/mUC prior to initiating EV. The researchers conclude that prior to receiving EV, most of the patients studied received platinum-based chemotherapy or a PD-1/L1, and HRU and health care costs were substantial. These findings establish a critical baseline for evaluating the future impact of EV across this patient population.
The article, “Treatment Patterns, Healthcare Resource Utilization, and Costs Among Patients Diagnosed With Locally Advanced/Metastatic Urothelial Carcinoma Prior to Receiving Enfortumab Vedotin: A Real-World Evidence Study,” was published in the International Journal of Urology.